|
|||||
|
|
Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia |
|
| Authors: | D. Middleton,A. S. Diler,A. Meenagh,C. Sleator,& P. A. Gourraud |
| Affiliation: | Transplant Immunology, Liverpool University Hospital and School of Infection and Immunity, Liverpool University, Liverpool, UK; Department of Medical Biology, Istanbul Medical Faculty, Istanbul, Turkey; Northern Ireland Histocompatibility and Immunogenetics Laboratory, City Hospital, Belfast, UK; INSERM U 558, Department of Epidemiology, Faculty of Medicine, University of Toulouse, Toulouse, France; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA |
| Abstract: | We have analysed the frequency of killer immunoglobulin-like receptors (KIR) in cohorts of patients from Turkey with acute lymphocyte leukaemia ( n = 52), acute myeloid leukaemia ( n = 54) and chronic myeloid leukaemia (CML) ( n = 52) and compared the results with 154 controls. We also examined the frequencies of human leucocyte antigen (HLA)-C groups, -Bw4, -Bw6 and where appropriate the combination of the KIR gene and its ligand. We found several statistically significant results between the patients and the controls. We proposed a model in CML of protection via KIR2DL2 and/or KIR2DS2 with the presence of the ligand HLA-C1 group and susceptibility via HLA-Bw4 homozygosity (i.e. absence of HLA-Bw6). |
| Keywords: | leukaemia killer immunoglobulin-like receptors human leucocyte antigen ligands |